Claim 1: a Pharmaceutical Tablet comprises a Core and an outer layer, the core comprising ACETYLSALICYLIC ACID or one of its pharmaceutically acceptable Salts and comprising the outer layer Clopidogrel or one of its pharmaceutically acceptable salts,The core is separated from the outer layer to a Coating gastroresistant Three layers composed of a layer sandwiched between two Insulating layers, comprising at least a gastroresistant Coating gastroresistant Polymer and at least 40% by weight of TALC, with respect to the weight of the po L u00edmero Gastro.Claim 4: The Tablet according to any of the preceding Claims, in which the composition of the Insulating layers is identical and comprises hydroxypropylmethylcellulose (HPMC), hydroxypropyl Cellulose and / or polyvinyl alcohol.Claim 5: The Tablet according to any of the preceding Claims, wherein the Clopidogrel and ACETYLSALICYLIC ACID are present in a molar ratio of Clopidogrel / aspirin between 0.35 and 0.45.Claim 6: a process to produce a compressed according to any one of claims 1 to 5, Said method comprising the following steps: (i) preparing a Core comprising ACETYLSALICYLIC ACID or one of its pharmaceutically acceptable salts, Coating (ii) The Core, so as to obtain a Core CoatedCoated with a layer of three layers composed of a gastroresistant inserted between two Insulating layers, (iii) Coated on the core coated Compression obtained in STEP (ii) with the Powder comprising Clopidogrel or one of its pharmaceutically acceptable salts, to obtain This Way a tablet.Claim 13: The Tablet according to any one of claims 1 to 5, for use in the treatment of a Pathological condition induced platelet aggregation, including Stable or unstable angina, disorders of the Cardiovascular System and cerebrovascular Disorder, for example S VTE associated with atherosclerosis and diabetes, such as unstable angina, Stroke,Restenosis after endarterectomy or Angioplasty, the insertion of endovascular prosthesis metal associated with t
